Skip to content

Main Navigation

Fennec Pharmaceuticals
Fennec Pharmaceuticals
  • For Families
    • Advocacy Groups
    • Family Stories
    • Named Patient Access
  • Product
  • Science
    • Cisplatin-Induced Hearing Loss
  • About Us
    • Our Mission
    • Our Team
  • Investors
    • Corporate Profile
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
  • Contact Us
  • For Families
    • Advocacy Groups
    • Family Stories
    • Named Patient Access
  • Product
  • Science
    • Cisplatin-Induced Hearing Loss
  • About Us
    • Our Mission
    • Our Team
  • Investors
    • Corporate Profile
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
  • Contact Us

Helping kids hear the future

Fennec Pharmaceuticals is a biotechnology company dedicated to improving the lives of children with cancer who experience hearing loss as a result of chemotherapy.

Discover what we stand for
Explore what we’re focused on
Our productNOW APPROVED

Latest News

  • 2023-01-31T06:00:00Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
  • 2023-01-25T07:19:00Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients
  • 2022-11-11T07:10:00Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
See More

Resources

For Investors
For Families

You are now leaving Fennec Pharmaceuticals to access a product-specific website.

Please visit us again soon!

Continue

Fennec® is a registered trademark of Fennec Pharmaceuticals Inc.
©2022 Fennec Pharmaceuticals Inc. All rights reserved. FEN-1070-v2 10/22

  • Privacy Policy
  • Terms & Conditions
  • Careers
  • Sitemap